GlassScriptPhysician profile
Aspasia E Draga
NPI 1992896518
$3,740.74
in general payments reported to CMS, 2019-2025
18 companies · $637 in 2025
The $637 reported for 2025 was more than what a typical Ophthalmology provider received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $823 · 2020: $300 · 2021: $181 · 2022: $537 · 2023: $588 · 2024: $675 · 2025: $637.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,900.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,899.91 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $1,690.57 | 2019-2025 | Clareon, Centurion, Luxor |
| Bausch & Lomb Americas INC. | $275.00 | 2024-2025 | Envista Mx60 Iol, Miebo, Xiidra |
| Sun Pharmaceutical Industries INC. | $242.31 | 2019-2023 | Cequa |
| Glaukos Corporation | $232.28 | 2019-2025 | Idosetr |
| Carl Zeiss Meditec Cataract Technology INC. | $153.64 | 2019 | |
| Kala Pharmaceuticals, INC. | $153.63 | 2019 | |
| Abbvie INC. | $131.13 | 2022 | |
| Johnson & Johnson Surgical Vision, INC. | $125.55 | 2020-2022 | |
| Genentech USA, INC. | $125.00 | 2023 | Vabysmo |
| Omeros Corporation | $124.90 | 2019 | |
| Tarsus Pharmaceuticals, INC. | $123.83 | 2025 | Xdemvy |
| Recordati_rare_diseases_inc. | $122.19 | 2024 | Cystadrops |
| Carl Zeiss Meditec USA, INC. | $109.60 | 2021 | |
| Lensar, INC. | $50.68 | 2025 | Lensar Laser System |
| Aerie Pharmaceuticals, INC. | $24.40 | 2020 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biotissue Holdings INC. | $23.36 | 2022 | |
| Novartis Pharmaceuticals Corporation | $17.22 | 2019 | |
| Allergan, INC. | $15.45 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Aspasia Draga listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.